Applying next generation sequencing with microdroplet PCR to determine the disease-causing mutations in retinal dystrophies

Autor: Leera D’Souza, Keith Wetherby, Xinjing Wang, Wadih M. Zein, Yang C. Fann, Amy Turriff, Chimere Roberson, Kory R. Johnson, Hong He, Angela Villarta
Rok vydání: 2017
Předmět:
Zdroj: BMC Ophthalmology, Vol 17, Iss 1, Pp 1-15 (2017)
BMC Ophthalmology
ISSN: 1471-2415
DOI: 10.1186/s12886-017-0549-5
Popis: Background Inherited Retinal dystrophy (IRD) is a broad group of inherited retinal disorders with heterogeneous genotypes and phenotypes. Next generation sequencing (NGS) methods have been broadly applied for analyzing patients with IRD. Here we report a novel approach to enrich the target gene panel by microdroplet PCR. Methods This assay involved a primer library which targeted 3071 amplicons from 2078 exons comprised of 184 genes involved in retinal function and/or retinal development. We amplified the target regions using the RainDance target enrichment PCR method and sequenced the products using the MiSeq NGS platform. Results In this study, we analyzed 82 samples from 67 families with IRD. Bioinformatics analysis indicated that this procedure was able to reach 99% coverage of target sequences with an average sequence depth of reads at 119×. The variants detected by this study were filtered, validated, and prioritized by pathogenicity analysis. Genotypes and phenotypes were correlated by determining a consistent relationship in 38 propands (56.7%). Pathogenic variants in genes related to retinal function were found in another 11 probands (16.4%), but the clinical correlations showed inconsistencies and insufficiencies in these patients. Conclusions The application of NGS in IRD clinical molecular diagnosis provides a powerful approach to exploring the etiology and pathology in patients. It is important for the clinical laboratory to interpret the molecular findings in the context of patient clinical presentations because accurate interpretation of pathogenic variants is critical for delivering solid clinical molecular diagnosis to clinicians and patients and improving the standard care of patients. Electronic supplementary material The online version of this article (doi:10.1186/s12886-017-0549-5) contains supplementary material, which is available to authorized users.
Databáze: OpenAIRE
Externí odkaz: